In the primary efficacy phase (months 0-6), patients were randomly assigned to receive tesamorelin [2 mg subcutaneous (SC) every day] or placebo in a 2:1 ratio
Keep it away from children and pets
Legacy Pregnancy Letter Categories (Historical reference only no longer current FDA standard) CategoryDefinitionAAdequate and well-controlled studies in pregnant women failed to demonstrate a risk to the fetus in the first trimester, and there is no evidence of risk in later trimesters.BAnimal reproduction studies failed to demonstrate fetal risk, but there are no adequate and well-controlled studies in pregnant women
Monitor for warning signs such as fever, severe pain, or persistent swelling, while implementing supportive care measures including adequate rest, proper nutrition, and stress reduction techniques
Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord
Nutr Metab (Lond) 20 , 32 (2023)
